Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield MN step therapy Prior Auth …
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - MinnesotaPolicy N/A

    Step Therapy Requirements for Provider Administered Specialty Medications

    Customize your policy alerts

    Sign up for all blue cross blue shield - minnesota policy alerts

    Know when blue cross blue shield - minnesota releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines step therapy requirements for provider-administered specialty drugs, including preferred alternative agents and applicable billing codes; affects providers who administer specialty medications for Blue Cross Blue Shield licensees (Minnesota).

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerBlue Cross Blue Shield - Minnesota
    PolicyStep Therapy Requirements for Provider Administered Specialty Medications
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and document that the member has trialed the designated preferred alternative agent(s) listed in the step therapy table before requesting coverage of the specialty medication.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    multipleprovider-administered specialty drugs listed with step therapy requirements
    codes providedHCPCS/Q-codes and J-codes referenced for drugs
    exception processmember exception available via determination process

    Coverage and Step Therapy Criteria

    inv-01: General coverage prerequisites

    Coverage for a provider-administered specialty medication is allowed when ALL of the following are met:

    Step therapy coverage prerequisites: The medication is a provider-administered specialty drug; the drug is being used to treat a medically accepted indication; dose, frequency and duration do not exceed the safety and efficacy data supporting the medically accepted indication.

    From policy introduction

    inv-02: Drug-specific step therapy

    For each listed drug, coverage requires following the specific step:

    Drug-specific step therapy: Member must have tried at least one designated preferred alternative agent (or biosimilar) listed in the table prior to coverage of the requested provider-administered specialty medication, unless the table notes otherwise (for example, oncology-specific exceptions).

    See drug-by-drug table entries

    Several table entries identify oncology exceptions where the usual preferred-alternative step is different or does not apply. For example, certain products listed in the table (e.g., some viscosupplement and infliximab entries) include a specific note: “For oncology indications only — = Inflectra” or list alternative oncology-specific products such as Mvasi or Zirabev as the designated option. Providers should follow the table’s row-level oncology notation when the requested use is for an oncology indication.

    Use of a provider-administered specialty medication without first meeting the policy’s step therapy requirements (i.e., when a listed preferred alternative or biosimilar has not been tried as required by the table) is not supported by this policy and may be considered not medically necessary. Requests are subject to prior authorization and may be denied if the step therapy prerequisites are not documented.

    Initial Therapy Requirements

    inv-14: Initial therapy requirement

    Initial therapy rules from the table

    Initial step: Prior to approval of the requested provider-administered specialty agent, try one of the preferred alternative agents listed next to the requested medication in the step-therapy table (or an indicated biosimilar), unless the table entry explicitly states the requirement does not apply for the indication (for example, certain oncology indications).

    Drug-specific table entries

    Continuation Therapy

    inv-15: Continuation therapy

    Continuation requires ongoing adherence to indication and dose limits.

    Continuation: Ongoing therapy must continue to meet the medically accepted indication and the dosing, frequency, and duration limitations stated in the policy; documentation should support continued medical necessity and adherence to the policy's dose/frequency limits.

    Policy general rule

    Step Therapy Table and Rules

    Requested Provider‑Administered Specialty MedicationPreferred alternative(s) (member must try one unless noted)Notes / exceptions
    Aralast NP (J0256)Prolastin C
    Glassia (J0257)Zemaira
    Soliris (J1299)Ultomiris (J1303)
    Actemra IV (J3262)No preferred alternative listed
    Avzivi (J9035 / Q5107 / Q5118)For oncology indications: Mvasi or ZirabevOncology exception — different alternatives specified
    Hyaluronic acid viscosupplements (J7320, J7321, J7322, J7327)Preferred alternatives vary; examples include GenVisc 850, Hyalgan, Hymovis; for oncology indications Synvisc/Synvisc One or Euflexxa may be listedSome entries note oncology-specific alternatives
    Infliximab products (J1745 and related Q-codes)Biosimilar alternatives such as Avsola / Inflectra noted where applicableOncology indications may have different listed alternatives
    Stimulating products (e.g., Rolvedon J1449; Nyvepria Q5122; Ryzneuta J9361)Biosimilar or Rolvedon for certain indications; Neulasta/Neulasta OnPro and similar agents referenced as alternativesSpecific agent-level notes apply (see table)
    Retinal disorder agents (Eylea J0178/J0177; Lucentis J0179; Eydenzelt/Q5150; Enzeevu/Q5149)Avastin (J2778) is listed as the initial preferred agent; then one of the listed higher‑cost agents may be trialedAvastin-first requirement for certain retinal agents; see agent-specific rows
    Rituximab products (Q5115, Q5119; Riabni Q5155; Riabni J9312)Preferred rituximab biosimilars/products are listed (e.g., Truxima, Ruxience); trial of designated biosimilar/product required
    Trastuzumab products (J9355, J9356; Q5146, Q5113)Preferred trastuzumab products/biosimilars are listed (e.g., Trazimera, Kanjinti); trial of designated agent is required except as notedSee table for indication‑specific exceptions

    Relevant Billing and Product Codes

    Examples from autoimmune and AAT deficiencyHCPCS
    J0256Aralast NP / referenced
    J0257Glassia
    J1299Soliris / other
    J1303Ultomiris
    J3262Actemra IV
    Q5156Avtozma IV / tocilizumab-anoh IV
    Viscosupplement and infliximab product codesHCPCS
    J7320Gelsyn-3 / hyaluronic acid products
    J7321GenVisc 850 / Visco products
    J7322Hyalan products
    J1745Infliximab
    Q5121Avsola
    Supportive care, retinal, rituximab and trastuzumab product codesHCPCS
    J1449Rolvedon
    Q5122Nyvepria
    J9361Ryzneuta
    Q5150Eydenzelt / Lucentis related Q-code
    J0179Lucentis J-code
    J2778Avastin intravitreal
    Q5149Enzeevu / related
    J0178Eylea J-code
    J0177Eylea HD J-code
    Q5155Rituximab-related Q-code
    1–10 of 14
    1/2

    What Providers Must Do

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required per step therapy. Members must have tried the listed preferred alternatives before coverage of the requested provider-administered specialty medication.

    • Prior authorization required for provider-administered specialty drugs subject to step therapy
    • Coverage contingent on trying designated preferred alternative(s) listed in the step therapy table
    Step Therapy

    Step Therapy Requirement

    Providers must follow the step therapy table and the designated preferred alternatives. The member must have tried (and failed, is intolerant to, or has a documented contraindication to) at least one of the listed preferred alternatives prior to approval of the requested specialty drug unless an exception is documented.

    • Use the step therapy table to identify required preferred alternative agents for the specific diagnosis and J/Q-code
    • If a preferred alternative is not appropriate, document the clinical reason (failure, intolerance, contraindication, or other medical rationale)

    Applicable Site of Care

    Note

    Policy applies to provider‑administered settings

    This policy applies to provider‑administered settings (office/infusion); the document does not impose specific site‑of‑care limitations.

    Biosimilar and Retinal Agent Notes

    Billing Rule

    Avastin required as initial preferred retinal agent

    For listed retinal agents (Enzeevu, Eydenzelt, Lucentis), Avastin is specified as the initial preferred agent to be tried prior to coverage of higher‑cost agents; the table then allows one of the listed agents after Avastin.

    • Enzeevu / Eydenzelt / Lucentis: “Avastin Then one of the following” (table language).
    • Retinal agent codes (e.g., J2778 for Avastin) are listed in the table entries referenced.

    Key Definitions

    Provider administered specialty drug — definition and key points
    DefinitionA specialty medication that is administered by a healthcare provider rather than self‑administered by the member.
    ScopeApplies to medications listed in the policy's step therapy table that are given in a provider‑administered setting.
    Coverage prerequisiteThe drug must be used to treat a medically accepted indication.
    Safety constraintDose, frequency and duration may not exceed the safety and efficacy data supporting the indication.
    Action for providersPrior authorization and adherence to step therapy (try designated preferred alternative first) are required per the policy table.

    Background and Scope

    Provider-administered specialty medications span multiple therapeutic areas, including autoimmune disorders, oncology, retinal disorders, and supportive care. The policy requires use of preferred alternatives or biosimilars where specified to align with safety, efficacy, and cost-effective care, and applies when the medication is a provider-administered specialty drug used for a medically accepted indication with appropriate dose, frequency, and duration.

    Policy Summary
    PayerBlue Cross Blue Shield - Minnesota
    PolicyStep Therapy Requirements for Provider Administered Specialty Medications
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and document that the member has trialed the designated preferred alternative agent(s) listed in the step therapy table before requesting coverage of the specialty medication.
    SourceLink
    On This Page
    Coverage and Step Therapy CriteriaInitial Therapy RequirementsContinuation TherapyStep Therapy Table and RulesRelevant Billing and Product CodesWhat Providers Must DoApplicable Site of CareBiosimilar and Retinal Agent NotesKey DefinitionsBackground and Scope
    Documentation Required

    Required Documentation

    Documentation submitted with the prior authorization request must support the medical indication, dose, frequency, and duration of therapy. Include clinical notes, prior medication trials (dates, doses, responses), laboratory or diagnostic results when applicable, and rationale why preferred alternatives are not appropriate if step therapy was not followed.

    • Support indication, dose, frequency, and duration for the requested use
    • Provide prior treatment history showing trial(s) of preferred alternative(s) with dates and clinical response
    • Include relevant labs, imaging, and clinical notes to justify therapy and to show use does not exceed safety/efficacy limits
    Denial Risk

    Denial for Unmet Step Therapy

    Requests that do not meet the step therapy requirements (no documented trial of a required preferred alternative and no documented exception) may be denied.

    • Denial may occur if preferred alternative(s) listed in the step therapy table were not tried and no clinical exception is documented